Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Authors
Keywords
-
Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume -, Issue -, Pages -
Publisher
Massachusetts Medical Society
Online
2023-10-21
DOI
10.1056/nejmoa2306441
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
- (2023) Christos Chouaid et al. ADVANCES IN THERAPY
- Chemotherapy-induced thrombocytopenia: literature review
- (2023) Ai Gao et al. Discover Oncology
- Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
- (2023) Sai-Hong Ignatius Ou et al. JTO Clinical and Research Reports
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
- (2022) Anna Minchom et al. LUNG CANCER
- Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis
- (2022) Suzy Van Sanden et al. Targeted Oncology
- Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer
- (2022) Julie Vanderpoel et al. JOURNAL OF MEDICAL ECONOMICS
- EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
- (2022) Jiabao Hou et al. Biomarker Research
- Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors
- (2022) Nicolas Girard et al. Clinical Lung Cancer
- Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study.
- (2022) Robert E. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study.
- (2022) Mike Gart et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency, underdiagnosis and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real‐world genomic datasets
- (2022) Santiago Viteri et al. Molecular Oncology
- Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications
- (2022) Byoung Chul Cho et al. Clinical Lung Cancer
- Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review
- (2021) Heather Burnett et al. PLoS One
- P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC
- (2021) T. Agrawal et al. Journal of Thoracic Oncology
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
- (2021) Keunchil Park et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations
- (2021) Lyudmila Bazhenova et al. LUNG CANCER
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
- (2020) Jiyeon Yun et al. Cancer Discovery
- Amivantamab (JNJ-61186372), An Fc Enhanced EGFR/cMet Bispecific Antibody Induces Receptor Downmodulation And Anti-tumor Activity By Monocyte/Macrophage Trogocytosis
- (2020) Smruthi Vijayaraghavan et al. MOLECULAR CANCER THERAPEUTICS
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer
- (2018) Jonathan W. Riess et al. Journal of Thoracic Oncology
- Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
- (2018) Jacqulyne P. Robichaux et al. NATURE MEDICINE
- A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors
- (2016) Sheri L. Moores et al. CANCER RESEARCH
- Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
- (2013) Geoffrey R. Oxnard et al. Journal of Thoracic Oncology
- EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
- (2013) M. E. Arcila et al. MOLECULAR CANCER THERAPEUTICS
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started